Drug intelligence / Profile preview

freethiadine

Development stage: Phase 1
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules
Administration: Oral

Overview

Freethiadine is a pharmaceutical compound developed as an inhibitor of the hepatitis B virus (HBV) capsid. It is being investigated for its potential therapeutic application in the treatment of chronic hepatitis B infection. The drug acts by targeting and inhibiting the assembly or function of the HBV capsid, thereby interfering with viral replication. Freethiadine is available in tablet form and has been developed by Sunshine Lake Pharma[1][2][9].

Brand names: freethiadine
Other names: freethiadine

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on freethiadine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on freethiadine.

Explore the full profile